NASDAQ : FENC

Fennec Pharmaceuticals Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 10.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 359.09M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Details

NameFennec Pharmaceuticals Inc.
SectorHealthcare
IndustryBiotechnology
Employees35
Founded1996
Ipo Date2001-06-05
CeoJeffrey Hackman
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA31447P1009
Cusip31447P100
Cik0001211583
Sic2836

Key executives

NameTitle
Jeffrey S. HackmanChief Executive Officer and Director
Robert C. AndradeChief Financial Officer
Dr. Pierre S. Sayad M.S., Ph.D.Chief Medical Officer
Terry EvansChief Commercial Officer
Christiana Cioffi M.B.A.Chief Strategy Officer
Mark GowlandController
Lei FangPresident of Pharstat Inc

Contact

Address68 TW Alexander Drive, PO Box 13628, Research Triangle Park, North Carolina 27709, United States
Phone919 636 4530
Websitehttps://www.fennecpharma.com